Back to Search Start Over

Co-delivery of Interleukin-12 and doxorubicin loaded Nano-delivery system for enhanced immunotherapy with polarization toward M1-type Macrophages.

Authors :
Li, Tushuai
Liu, Zhihong
Fu, Xiao
Chen, Yongquan
Zhu, Shenglong
Zhang, Jie
Source :
European Journal of Pharmaceutics & Biopharmaceutics. Aug2022, Vol. 177, p175-183. 9p.
Publication Year :
2022

Abstract

[Display omitted] Chemo-immunotherapy has gained increasing attention as one of the most promising combination therapy strategies to battle cancer. In this study, the therapeutic nanoparticles (TNPs) co-delivering doxorubicin (DOX) and IL-12 (IL-12) were developed for chemo-immunotherapy combination therapy on liver cancer. TNPs were synthesized based on the ionic interactions between cationic chitosan (Ch) and anionic poly-(glutamic acid) (PGA). DOX and IL-12 loaded in TNPs presented prolonged circulation in blood, efficient accumulation in tumors, and internalization in tumor cells. After that, DOX and IL-12 were co-released in the tumor microenvironment. The locally responsive property of TNPs could subsequently re-educate macrophages. More significantly, TNPs with no obvious side effects can remarkably inhibit the H22 tumor growth in vivo. A low dosage of loaded IL-12 in TNPs can effectively polarize macrophages toward the M1 phenotype to reduce tumor burden, further enhancing the antitumor efficacy. Our results suggest that the self-stabilized TNPs could be a secure and effective drug carrier for intravenous administration when deprived of protective agents. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
09396411
Volume :
177
Database :
Academic Search Index
Journal :
European Journal of Pharmaceutics & Biopharmaceutics
Publication Type :
Academic Journal
Accession number :
158368370
Full Text :
https://doi.org/10.1016/j.ejpb.2022.07.002